Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

Neuroscience

Volumn 303, Issue , 2015, Pages 42-50

  Liu, W ^b   Jalewa, J ^a   Sharma, M ^a   Li, G ^b   Li, L ^b   Holscher C ^a,b  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Basal ganglia; Growth factor; Incretin; Insulin; Neurodegeneration

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; B CELL LYMPHOMA 2 PROTEIN; BINDING PROTEIN; DOPAMINE; EXENDIN 4; LIRAGLUTIDE; LIXISENATIDE; PROTEIN BAX; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; PEPTIDE; VENOM; ZP10A PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BLOOD LEVEL; BRAIN FUNCTION; CATALEPSY TEST; DOPAMINE METABOLISM; DRUG EFFECT; DRUG RESPONSE; EXPLORATORY BEHAVIOR TEST; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; ROTAROD TEST; SUBSTANTIA NIGRA; ANIMAL; APOPTOSIS; C57BL MOUSE; CATALEPSY; CHEMICALLY INDUCED; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; APOPTOSIS; BASAL GANGLIA; CATALEPSY; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; LIRAGLUTIDE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PEPTIDES; ROTAROD PERFORMANCE TEST; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VENOMS;

EID: 84936871959     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.06.054     Document Type: Article

References (37)

1. Aviles-Olmos I., Dickson J., Kefalopoulou Z., Djamshidian A., Ell P., Soderlund T., Whitton P., Wyse R., Isaacs T., Lees A., Limousin P., Foltynie T. Exenatide and the treatment of patients with Parkinson's disease. J Clin Investig 2013, 123:2730-2736.
2. Aviles-Olmos I., Dickson J., Kefalopoulou Z., Djamshidian A., Kahan J., Fmedsci P.E., Whitton P., Wyse R., Isaacs T., Lees A., Limousin P., Foltynie T. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinson's Dis 2014, 4:337-344.
3. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
4. Bertilsson G., Patrone C., Zachrisson O., Andersson A., Dannaeus K., Heidrich J., Kortesmaa J., Mercer A., Nielsen E., Ronnholm H., Wikstrom L. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008, 86:326-338.
5. Bondolfi L., Calhoun M., Ermini F., Kuhn H.G., Wiederhold K.H., Walker L., Staufenbiel M., Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 2002, 22:515-522.
6. Briyal S., Shah S., Gulati A. Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia. Neuroscience 2014, 281C:269-281.
7. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013, 17:819-837.
8. DellaValle B., Hempel C., Johansen F.F., Kurtzhals J.A. GLP-1 improves neuropathology after murine cold lesion brain trauma. Ann Clin Transl Neurol 2014, 1:721-732.
9. Elkinson S., Keating G.M. Lixisenatide: first global approval. Drugs 2013, 73:383-391.
10. Gerlach M., Riederer P., Przuntek H., Youdim M.B. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 1991, 208:273-286.
11. Glover V., Gibb C., Sandler M. The role of MAO in MPTP toxicity-a review. J Neural Transmission Supplementum 1986, 20:65-76.
12. Hakon J., Ruscher K., Romner B., Tomasevic G. Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury. PLoS One 2015, 10.1371/journal.pone.0120074.
13. Harkavyi A., Abuirmeileh A., Lever R., Kingsbury A.E., Biggs C.S., Whitton P.S. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 2008, 5:11-19.
14. Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 2013, 221:31-41.
15. Holscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases. Acta Physiol Sin 2014, 66:497-510.
16. Holscher C. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. Biochem Soc Trans 2014, 42:593-599.
17. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012, 13:33-38.
18. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obesity Related Metabolic Disord 2003, 27:313-318.
19. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002, 18:7-14.
20. Kim S., Moon M., Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol 2009, 202:431-439.
21. Kinemuchi H., Fowler C.J., Tipton K.F. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) and its relevance to parkinson's disease. Neurochem Int 1987, 11:359-373.
22. Kopin I.J., Markey S.P. MPTP toxicity: implications for research in Parkinson's disease. Ann Rev Neurosci 1988, 11:81-96.
23. Langston J.W. Parkinson's disease: current and future challenges. Neurotoxicology 2002, 23:443-450.
24. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., Powers K., Shen H., Egan J.M., Sambamurti K., Brossi A., Lahiri D.K., Mattson M.P., Hoffer B.J., Wang Y., Greig N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009, 106:1285-1290.
25. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
26. McClean P., Parthsarathy V., Faivre E., Hölscher C. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011, 31:6587-6594.
27. McClean P.L., Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 2014, 76(Pt A):57-67.
28. McClean P.L., Holscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 2014, 86C:241-258.
29. Mickiewicz A.L., Kordower J.H. GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets 2011, 10:703-711.
30. Nakamura S., Vincent S.R. Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+. Neurosci Lett 1986, 65:321-325.
31. Ohtake N., Saito M., Eto M., Seki K. Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex. Regulat Peptides 2014, 190-191:1-11.
32. Perry T.A., Greig N.H. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 2004, 5:565-571.
33. Raun K., von Voss P., Knudsen L.B. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 2007, 15:1710-1716.
34. Sato K., Kameda M., Yasuhara T., Agari T., Baba T., Wang F., Shinko A., Wakamori T., Toyoshima A., Takeuchi H., Sasaki T., Sasada S., Kondo A., Borlongan C.V., Matsumae M., Date I. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci 2013, 14:21513-21524.
35. Sharma M., Jalewa J., Holscher C. Neuroprotective and anti-apoptotic effects of Liraglutide on SH-SY5Y cells exposed to Methylglyoxal stress. J Neurochem 2013, 128:459-471.
36. Smith T.S., Bennett J.P. Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions. Brain Res 1997, 765:183-188.
37. Tan T., Bloom S. Gut hormones as therapeutic agents in treatment of diabetes and obesity. Curr Opin Pharmacol 2013, 13:996-1001.